Radium Ra 223 Dichloride

• SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial Recruiting
  2024-512132-29-00 Phase II 1 country Swiss Group for Clinical Cancer Research
• Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting
  2022-502254-13-00 Phase III 1 country UZ Leuven
• Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended
  2023-505830-89-00 Phase IV 10 countries Bayer AG; Bayer Consumer Care AG
• DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Ended
  2024-513867-19-00 Phase III 2 countries Memorial Sloan Kettering Cancer Center
• A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly sympto… Ended
  2023-510453-41-00 Phase III 8 countries European Organisation For Research And Treatment Of Cancer
• DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTA… Ended
  2024-518985-29-02 Phase I (FiH) 1 country Amsterdam UMC Stichting
• Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic cas… Ended
  2024-511660-89-00 Phase II 1 country Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Showing 1–7 of 7 trials